Aryl-alkyl-lysines: Novel agents for treatment of C. difficile infection

dc.contributor.authorGhosh, Chandradhishen
dc.contributor.authorAbdelKhalek, Ahmeden
dc.contributor.authorMohammad, Haroonen
dc.contributor.authorSeleem, Mohamed N.en
dc.contributor.authorHaldar, Jayantaen
dc.date.accessioned2020-09-21T16:17:45Zen
dc.date.available2020-09-21T16:17:45Zen
dc.date.issued2020-03-27en
dc.date.updated2020-09-21T16:17:42Zen
dc.description.abstractClostridium difficile infections (CDIs) are a growing health concern worldwide. The recalcitrance of C. difficile spores to currently available treatments and concomitant virulence of vegetative cells has made it imperative to develop newer modalities of treatment. Aryl-alkyl-lysines have been earlier reported to possess antimicrobial activity against pathogenic bacteria, fungi, and parasites. Their broad spectrum of activity is attributed to their ability to infiltrate microbial membranes. Herein, we report the activity of aryl-alkyl-lysines against C. difficile and associated pathogens. The most active compound NCK-10 displayed activity comparable to the clinically-used antibiotic vancomycin. Indeed, against certain C. difficile strains, NCK-10 was more active than vancomycin in vitro. Additionally, NCK-10 exhibited limited permeation across the intestinal tract as assessed via a Caco-2 bidirectional permeability assay. Overall, the findings suggest aryl-alkyl-lysines warrant further investigation as novel agents to treat CDI.en
dc.description.versionPublished versionen
dc.format.extent7 page(s)en
dc.format.mediumElectronicen
dc.format.mimetypeapplication/pdfen
dc.identifierARTN 5624 (Article number)en
dc.identifier.doihttps://doi.org/10.1038/s41598-020-62496-9en
dc.identifier.eissn2045-2322en
dc.identifier.issn2045-2322en
dc.identifier.issue1en
dc.identifier.orcidSeleem, Mohamed [0000-0003-0939-0458]en
dc.identifier.other10.1038/s41598-020-62496-9 (PII)en
dc.identifier.pmid32221399 (pubmed)en
dc.identifier.urihttp://hdl.handle.net/10919/100044en
dc.identifier.volume10en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectANTIMICROBIAL PEPTIDESen
dc.subjectIN-VITROen
dc.subjectVANCOMYCINen
dc.subjectMEMBRANEen
dc.subjectANTIBIOTICSen
dc.subjectSUROTOMYCINen
dc.subjectRECURRENCEen
dc.subjectRESISTANCEen
dc.subjectDISCOVERYen
dc.subjectMIMICSen
dc.titleAryl-alkyl-lysines: Novel agents for treatment of C. difficile infectionen
dc.title.serialScientific Reportsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherArticleen
dc.type.otherJournalen
dcterms.dateAccepted2020-02-24en
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Biomedical Sciences and Pathobiologyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Techen
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Aryl-alkyl-lysines Novel agents for treatment of C. difficile infection.pdf
Size:
1.31 MB
Format:
Adobe Portable Document Format